XTrend
MenuXTrend

Stock Charts

Charts can help you clearly see the market trend.

MRNA

Moderna, Inc.

Bid28.53
Ask28.59
Change0.83
% Chg+ 3.00%
High28.62
Low27.11

Past performance is not an indication of future results.

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology & Medical Research

Stock Exchange

NASDAQ

Listing Date

07-12-2018

Trading Specifications
Minimum Price Fluctuation
--
Spreads as low as
--
Average Spreads
--
Minimum Lot Size
--
Commission
--
Trading Hours(GMT+2)
--
Maximum Trading Volume (lots)
--
News
Meta, Microsoft and Tesla rise premarket; Apple, McDonald’s fall
Moderna Q1 2025 slides: Revenue falls 35% as pipeline investments continue
Moderna’s losses narrow in Q1, says it plans to cut its costs by $1.7bn by 2027
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Moderna earnings beat by $0.66, revenue fell short of estimates
FTSE 100 Live: Lloyds, LSE, Whitbread results in spotlight, ahead of Apple and Amazon
FTSE 100 Live: Stocks in stalemate as exports slump, oil prices slide; Microsoft to lead US tech rebound
Novavax shares fall following WSJ report on FDA trial request
Moderna, Novavax shares dip as CDC panel suggests limiting COVID shot updates
Stock market today: S&P 500 ends lower after paring gains amid tariff uncertainty
XTrend

AFA REGIONAL SPONSOR

XTrendEnglish
XTrend
XTrend
XTrend
XTrend
XTrend